xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT05984810</url>
    </required_header>
    <id_info>
      <org_study_id>P23.018</org_study_id>
      <secondary_id>2023-000026-28</secondary_id>
      <secondary_id>NL82221.058.23</secondary_id>
      <nct_id>NCT05984810</nct_id>
    </id_info>
    <brief_title>NIR-Fluorescence Guided Surgical Resection of Neoadjuvant Treated Localized Pancreatic Cancer Using SGM-101</brief_title>
    <acronym>FLUOPANC-II</acronym>
    <official_title>A Performance Study of SGM-101, a Fluorochrome-labeled Anti-carcinoembryonic Antigen Monoclonal Antibody for Fluorescence-guided Imaging to Determine Local Extent and Resectability During Surgical Resection of Pancreatic Ductal Adenocarcinoma After Neoadjuvant Treatment</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Leiden University Medical Center</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
      <collaborator>
        <agency>Dutch Cancer Society</agency>
        <agency_class>Other</agency_class>
      </collaborator>
      <collaborator>
        <agency>Surgimab</agency>
        <agency_class>Industry</agency_class>
      </collaborator>
    </sponsors>
    <source>Leiden University Medical Center</source>
    <oversight_info>
      <has_dmc>Yes</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
      <is_us_export>No</is_us_export>
    </oversight_info>
    <brief_summary>
      <textblock>
        Pancreatic carcinoma has a dismal prognosis at time of diagnosis, due to late onset of&#xD;
        clinical symptoms, patients present with advance disease. Complete surgical resection is the&#xD;
        only potential curative treatment, however only a small percentage is eligible for upfront&#xD;
        total surgical resection due to extension into anatomical related important vascular&#xD;
        structures. Neoadjuvant chemo(radio)therapy has become the standard treatment modality for&#xD;
        non-primary resectable disease (borderline resectable and locally advanced pancreatic cancer&#xD;
        (LAPC)), where subsequent downstaging can make identification of the primary tumor more&#xD;
        challenging during surgery. Near-infrared (NIR) fluorescence imaging can aid surgeons by&#xD;
        providing real-time visualization of tumors, suspect lymph nodes and vital structures during&#xD;
        surgery. Additional intra-operative feedback could possibly reduce the frequency of positive&#xD;
        resection margins and increase complete removal of locally spread tumor and involved lymph&#xD;
        nodes and could thereby improve patient outcomes as well as overall survival. SGM-101 is a&#xD;
        targeted NIR-fluorophore, with specific binding capacity for Carcino Embryonic Antigen (CEA)&#xD;
        which is overexpressed on tumor cells in the gastro-intestinal tract, including pancreatic&#xD;
        cancer.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        Pancreatic cancer is a lethal cancer type and is continuously rising as cause of&#xD;
        cancer-related death in the Western World. Despite advances in surgical and systemic&#xD;
        treatment, the 5-year overall survival (OS) rate remains approximately 10%. This low survival&#xD;
        rate is mostly caused by late detection of disease due to the late onset of symptoms.&#xD;
        Therefore, most patients are diagnosed with advanced stage disease: at the time of diagnosis,&#xD;
        about 15% of patients has (borderline) resectable ((B)RPC) disease (stage I or II), 35%&#xD;
        locally advanced pancreatic cancer (LAPC, stage III), and 50% metastatic disease (stage IV).&#xD;
        The resectability of disease is determined by the extent of tumor contact with the superior&#xD;
        mesenteric artery, celiac artery, superior mesenteric vein, and portal vein.&#xD;
  &#xD;
        Over the last decade, preoperative chemo(radio)therapy has increasingly been used in an&#xD;
        attempt to downstage BRPC or LAPC and select patients with more favorable tumor biology for&#xD;
        resection, with the aim to reduce the chance for (early) recurrence. In essence, only&#xD;
        patients showing regression or stable disease without suspected metastatic disease are&#xD;
        considered for surgical exploration. However, preoperative therapy complicates the&#xD;
        preoperative radiological staging, because conventional imaging modalities cannot&#xD;
        differentiate between vital tumor tissue, inflammation and fibrosis induced by the&#xD;
        preoperative chemo(radio)therapy. As a consequence, vascular tumor involvement is often&#xD;
        overestimated and also hard to interpret with substantial interobserver variability.&#xD;
        Therefore, non-progressive disease following preoperative therapy regarding imaging and tumor&#xD;
        markers is usually an indication for surgical exploration to determine whether radical&#xD;
        resection is achievable.&#xD;
  &#xD;
        During surgical exploration preceding intended tumor resection, the surgeon has to assess the&#xD;
        extent of local (vascular) tumor involvement based on preoperative imaging and visual and&#xD;
        tactile senses. This visual intraoperative White Light Inspection (WLI) combined with tactile&#xD;
        feedback, are the main instruments for guidance and decision-making available to surgeons&#xD;
        nowadays. As a result of neoadjuvant therapy the appearance, dimensions, and tactile feedback&#xD;
        of the target lesion can be altered, mostly as a result of therapy-induced fibrosis, which&#xD;
        complicates the assessment of (local) invasiveness. Surgeons benefit from additional tools&#xD;
        that give them real-time directional feedback on local tumor status, which is one of the&#xD;
        strengths of optical molecular imaging techniques, like Near-infrared fluorescence (NIRF)&#xD;
        imaging. Near-infrared fluorescence (NIRF) imaging is an emerging important intraoperative&#xD;
        tool for enhancement of visual contrast and is able to provide real-time guidance in tumor&#xD;
        visualization and demarcation. Particularly the use of tumor-specific markers coupled to&#xD;
        fluorescent imaging moieties show great promise to improve intraoperative staging and allow&#xD;
        more radical cytoreductive surgery if considered resectable.&#xD;
  &#xD;
        The compound that will be studied in this trial is SGM-101, a CEA-specific chimeric antibody&#xD;
        conjugated with a NIR emitting moiety developed by SurgiMab (Montpellier, France). Anti-CEA&#xD;
        monoclonal antibodies have been used in more than 100 clinical studies without any toxicity&#xD;
        concerns. In addition, it has been shown that it is possible to link an anti-CEA monoclonal&#xD;
        antibody to a near-infrared (NIR) emitting fluorophore. Carcinoembryonic antigen (CEA) is a&#xD;
        tumor-specific marker that is highly expressed in a number of tumors of epithelial origin&#xD;
        (such as colorectal carcinoma and pancreas carcinoma) while it is minimally expressed in&#xD;
        normal adult tissues. CEA, among others like Carbohydrate Antigen 19-9 (CA 19-9) is used as&#xD;
        diagnostic and prognostic marker during different stages of malignant pancreatic disease.&#xD;
        From a previous study conducted in the LUMC with this compound in patients with (borderline)&#xD;
        resectable pancreatic cancer the investigators learned that near-infrared fluorescence&#xD;
        imaging of pancreatic tumors using a single dose up to 10mg of the anti-CEA targeted&#xD;
        fluorophore SGM-101 is safe, well-tolerated, feasible and effective. It results in specific&#xD;
        accumulation of SGM-101 in CEA-expressing primary tumors, peritoneal and liver metastases,&#xD;
        allowing real-time identification and guidance using intraoperative fluorescence imaging.&#xD;
        Furthermore, CEA expression on the targeted PDAC tissue is expected to be none to minimally&#xD;
        influenced by the neoadjuvant treatment, either FOLFIRINOX or a combination of Gemcitabine&#xD;
        with or without radiotherapy, as described by previous studies. In addition to experience in&#xD;
        pancreatic tumors, there is ample experience from finalized phase-II and ongoing phase-III&#xD;
        studies in patient with colorectal carcinoma. A recent study in colorectal cancer patients&#xD;
        showed that additional malignant lesions were detected and resected using NIR fluorescence&#xD;
        imaging in 6 out of 17 patients (35%). Moreover, an expansion on this study showed no SGM-101&#xD;
        related adverse events up to 15 milligrams in 75 patients. There were no trends or clinically&#xD;
        relevant changes in vital signs, ECGs or laboratory parameters reported. Any changes in the&#xD;
        laboratory results reported in the follow-up moments were related to the surgical procedure.&#xD;
        Best imaging results (according to the tumor to background ratio) were achieved with 10&#xD;
        milligrams injected 3 to 5 days prior to surgery.&#xD;
  &#xD;
        This study evaluates the yield of NIR-Fluorescence imaging as additional surgical-tool for&#xD;
        visualization and assessment of local extent and resectability status of neoadjuvant treated&#xD;
        localized pancreatic tumors, local lymph node-involvement as well as potential distant&#xD;
        metastatic disease using a single intravenous dose of 10mg SGM-101.&#xD;
  &#xD;
        Main objective: Determination of the performance of SGM-101 as a fluorescent tracer for&#xD;
        NIR-Fluorescence-guidance (FLI) during surgical pancreatic resections after neoadjuvant&#xD;
        therapy for assessment of (local) tumor extent and delineation of the primary tumor, local&#xD;
        lymph nodes and potential distant metastatic disease&#xD;
  &#xD;
        Design:&#xD;
  &#xD;
        Part A: This is a single-center prospective clinical cohort study in patients with&#xD;
        neoadjuvant treated non-primarily resectable ((borderline) resectable and locally advanced)&#xD;
        pancreatic cancer undergoing scheduled surgical resection. A total of 20 patients will be&#xD;
        prospectively enrolled in this study evaluating the performance of NIR-Fluorescence imaging&#xD;
        as an additional surgical-tool for the visualization and determination of the local extent of&#xD;
        primary tumor, lymph node-involvement and occult hepatic and peritoneal metastatic disease in&#xD;
        patients using a single dose of 10mg of SGM-101. The selected dose is based on the&#xD;
        pre-clinical and phase I/II results in patients with pancreatic and colorectal cancer.&#xD;
  &#xD;
        Part B: Part B is synchronous to part A, to compare and match the TdEV containing blood&#xD;
        samples from patients participating in part A this trial needs 20 healthy donor control blood&#xD;
        samples of 30mL to address our exploratory endpoints regarding TdEV's. Therefore in this&#xD;
        trial 20 healthy volunteers will be asked to participate as anonymous healthy blood donor of&#xD;
        30mL (3 EDTA tubes) peripheral venous blood for a single visit to donate healthy donor blood.&#xD;
        The control samples will be used anonymous and there is no further follow-up or additional&#xD;
        study related activities.&#xD;
  &#xD;
        Investigational drug: The Investigational Medicinal Product (IMP) used in part A is the&#xD;
        injectable conjugate SGM-101 is composed of a chimeric monoclonal antibody specific of CEA,&#xD;
        bound to a fluorochrome. SGM-101 is manufactured in compliance with Good Manufacturing&#xD;
        Practice (GMP). It is a sterile solution for injection supplied in 4 mL amber glass vial (5&#xD;
        mg/mL; 2,3 mL/vial). A dose of 10 mg SGM-101 will be administered intravenously over 30&#xD;
        minutes 3 to 5 (±4) days prior to surgery.&#xD;
  &#xD;
        Imaging system: The Investigational Medical Device (IMD) used in part A is the imaging system&#xD;
        that will be used in the study is a dedicated NIRF-camera system from Quest Medical Imaging&#xD;
        (Quest Medical Imaging, Olympus Europe) the Quest Spectrum 2/3.0 Platform, that is optimized&#xD;
        for measurements in the 700-800nm NIR-spectrum. For this device ample handling-experience for&#xD;
        end-users exists at the LUMC, gained from standard-of-care and research activities with&#xD;
        intra-operative NIRF-imaging.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">October 2023</start_date>
    <completion_date type="Anticipated">December 2024</completion_date>
    <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
    <phase>Phase 2</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>N/A</allocation>
      <intervention_model>Single Group Assignment</intervention_model>
      <primary_purpose>Treatment</primary_purpose>
      <masking>None (Open Label)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>Intra-operative visualization of neoadjuvant treated pancreatic tumors using Near-infrared fluorescence imaging,</measure>
      <time_frame>Surgery -</time_frame>
      <description>The ability to visualize the primary pancreatic tumor, the local tumor extent and resectability status, with adjacent lymph nodes. As well as potential distant metastatic lesions, using SGM-101 and dedicated NIR-imaging systems. Visualization is measured using the tumor-to-background ratio (TBR) in ex-vivo settings. A tumor-to-background ratio (TBR) of at least ≥1.5 provides sufficient contrast for adequate visualization/delineation and will therefore be used as cut-off value.</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Concordance between fluorescent signal and tumor status of resected tissue</measure>
      <time_frame>Through study completion, an average of 3 months</time_frame>
      <description>Concordance to pathology results with respect to the presence of cancer and the imaging assessment, based on fluorescent signal and the tumor status (incl. degree of CEA-expression) of biopsied or resected tissue, expressed as accuracy (%), sensitivity (%) and specificity (%)</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Concordance between fluorescent signal and tumor status of resection margins.</measure>
      <time_frame>Through study completion, an average of 3 months</time_frame>
      <description>Concordance to pathology results with respect to the presence of cancer and the imaging assessment, based on fluorescent signal and the tumor status (incl. degree of CEA-expression) of biopsied or resected tissue, expressed as accuracy (%), sensitivity (%) and specificity (%)</description>
    </secondary_outcome>
    <number_of_arms>1</number_of_arms>
    <enrollment type="Anticipated">20</enrollment>
    <condition>Pancreas Adenocarcinoma</condition>
    <arm_group>
      <arm_group_label>10mg, administered 3-5 days before surgery</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Drug: SGM-101 Intravenous single injection of the targeted NIR fluorophore SGM-101. This targeted 700nm fluorophore developed by SurgiMab S.A.S., Montpellier, France.&#xD;
  Device: Intraoperative near-infrared fluorescence imaging Intraoperative imaging will be performed with the following CE-marked near-infrared (NIR) fluorescence imaging system: Quest Spectrum imaging platform (v2/3.0). With a NIR-imaging system a potential fluorescent signal of the tumor can be evaluated. Furthermore, the Quest Spectrum platform will also be used for evaluation of ex-vivo fluorescence of resected tissue on the back table (Back table imaging) and pathology department (ex-vivo imaging), which shall be performed during and after every procedure.</description>
    </arm_group>
    <intervention>
      <intervention_type>Procedure</intervention_type>
      <intervention_name>Fluorescence-guided surgery using CEA-targeted fluorophore SGM-101</intervention_name>
      <description>Fluorescence-guided surgery using CEA-targeted fluorophore SGM-101</description>
      <arm_group_label>10mg, administered 3-5 days before surgery</arm_group_label>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          INCLUSION CRITERIA&#xD;
  &#xD;
          Part A: To be eligible for inclusion in this study, patients must meet all of the following&#xD;
          criteria:&#xD;
  &#xD;
            1. Signed informed consent prior to any study-mandated procedure;&#xD;
  &#xD;
            2. Patients aged over 18 years old;&#xD;
  &#xD;
            3. Has the ability to communicate well with the Investigator in the Dutch/English&#xD;
               language and willing to comply with the study restrictions.&#xD;
  &#xD;
            4. Neoadjuvant treated (borderline) resectable or locally advanced pancreatic cancer&#xD;
               scheduled for a surgical resection&#xD;
  &#xD;
          Part B: To be eligible for inclusion in this study, healthy volunteers must meet all of the&#xD;
          following criteria:&#xD;
  &#xD;
            1. Signed informed consent prior to any study-mandated procedure;&#xD;
  &#xD;
            2. Patients aged over 18 years old;&#xD;
  &#xD;
            3. Has the ability to communicate well with the Investigator in the Dutch/English&#xD;
               language.&#xD;
  &#xD;
          EXCLUSION CRITERIA&#xD;
  &#xD;
          Part A: To be eligible for conclusion in this study, patients must meet none of the&#xD;
          following criteria:&#xD;
  &#xD;
            1. History of clinically significant anaphylactic reactions;&#xD;
  &#xD;
            2. Previous administration of SGM-101;&#xD;
  &#xD;
            3. Pregnant women, or women giving breast feeding;&#xD;
  &#xD;
            4. Any condition that the investigator considers to be potentially jeopardizing the&#xD;
               patient's well-being or the study objectives.&#xD;
  &#xD;
          Part B: To be eligible for conclusion in this study, healthy volunteers must meet none of&#xD;
          the following criteria:&#xD;
  &#xD;
            1. Previous administration of SGM-101;&#xD;
  &#xD;
            2. Pregnant women, or women giving breast feeding;&#xD;
  &#xD;
            3. Any condition that the investigator considers to be potentially jeopardizing the&#xD;
               patient's well-being or the study objectives.&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>N/A</maximum_age>
      <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
    </eligibility>
    <location>
      <facility>
        <name>Leiden University Medical Center</name>
        <address>
          <city>Leiden</city>
          <zip>2300RC</zip>
          <country>Netherlands</country>
        </address>
      </facility>
    </location>
    <location_countries>
      <country>Netherlands</country>
    </location_countries>
    <verification_date>August 2023</verification_date>
    <study_first_submitted>July 25, 2023</study_first_submitted>
    <study_first_submitted_qc>August 2, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 9, 2023</study_first_posted>
    <last_update_submitted>August 2, 2023</last_update_submitted>
    <last_update_submitted_qc>August 2, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 9, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Principal Investigator</responsible_party_type>
      <investigator_affiliation>Leiden University Medical Center</investigator_affiliation>
      <investigator_full_name>Alexander Vahrmeijer</investigator_full_name>
      <investigator_title>Surgical oncologist, Head of Vahrmeijer Research Lab</investigator_title>
    </responsible_party>
    <keyword>Fluorescence Guided Surgery</keyword>
    <keyword>Pancreatic Ductal Adenocarcinoma</keyword>
    <keyword>Neoadjuvant therapy</keyword>
    <keyword>Near-Infrared (NIR) Fluorescence imaging</keyword>
    <keyword>CEA</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Adenocarcinoma</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>No</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT05984810
  org study id: P23.018
  secondary id: 2023-000026-28
  secondary id: NL82221.058.23
  nct id: NCT05984810
  lead sponsor: 
  collaborator: 
  collaborator: 
  has dmc: Yes
  is fda regulated drug: No
  is fda regulated device: No
  is us export: No
  Pancreatic carcinoma has a dismal prognosis at time of diagnosis, due to late onset of
        clinical symptoms, patients present with advance disease. Complete surgical resection is the
        only potential curative treatment, however only a small percentage is eligible for upfront
        total surgical resection due to extension into anatomical related important vascular
        structures. Neoadjuvant chemo(radio)therapy has become the standard treatment modality for
        non-primary resectable disease (borderline resectable and locally advanced pancreatic cancer
        (LAPC)), where subsequent downstaging can make identification of the primary tumor more
        challenging during surgery. Near-infrared (NIR) fluorescence imaging can aid surgeons by
        providing real-time visualization of tumors, suspect lymph nodes and vital structures during
        surgery. Additional intra-operative feedback could possibly reduce the frequency of positive
        resection margins and increase complete removal of locally spread tumor and involved lymph
        nodes and could thereby improve patient outcomes as well as overall survival. SGM-101 is a
        targeted NIR-fluorophore, with specific binding capacity for Carcino Embryonic Antigen (CEA)
        which is overexpressed on tumor cells in the gastro-intestinal tract, including pancreatic
        cancer.
  Pancreatic cancer is a lethal cancer type and is continuously rising as cause of
        cancer-related death in the Western World. Despite advances in surgical and systemic
        treatment, the 5-year overall survival (OS) rate remains approximately 10%. This low survival
        rate is mostly caused by late detection of disease due to the late onset of symptoms.
        Therefore, most patients are diagnosed with advanced stage disease: at the time of diagnosis,
        about 15% of patients has (borderline) resectable ((B)RPC) disease (stage I or II), 35%
        locally advanced pancreatic cancer (LAPC, stage III), and 50% metastatic disease (stage IV).
        The resectability of disease is determined by the extent of tumor contact with the superior
        mesenteric artery, celiac artery, superior mesenteric vein, and portal vein.
  
        Over the last decade, preoperative chemo(radio)therapy has increasingly been used in an
        attempt to downstage BRPC or LAPC and select patients with more favorable tumor biology for
        resection, with the aim to reduce the chance for (early) recurrence. In essence, only
        patients showing regression or stable disease without suspected metastatic disease are
        considered for surgical exploration. However, preoperative therapy complicates the
        preoperative radiological staging, because conventional imaging modalities cannot
        differentiate between vital tumor tissue, inflammation and fibrosis induced by the
        preoperative chemo(radio)therapy. As a consequence, vascular tumor involvement is often
        overestimated and also hard to interpret with substantial interobserver variability.
        Therefore, non-progressive disease following preoperative therapy regarding imaging and tumor
        markers is usually an indication for surgical exploration to determine whether radical
        resection is achievable.
  
        During surgical exploration preceding intended tumor resection, the surgeon has to assess the
        extent of local (vascular) tumor involvement based on preoperative imaging and visual and
        tactile senses. This visual intraoperative White Light Inspection (WLI) combined with tactile
        feedback, are the main instruments for guidance and decision-making available to surgeons
        nowadays. As a result of neoadjuvant therapy the appearance, dimensions, and tactile feedback
        of the target lesion can be altered, mostly as a result of therapy-induced fibrosis, which
        complicates the assessment of (local) invasiveness. Surgeons benefit from additional tools
        that give them real-time directional feedback on local tumor status, which is one of the
        strengths of optical molecular imaging techniques, like Near-infrared fluorescence (NIRF)
        imaging. Near-infrared fluorescence (NIRF) imaging is an emerging important intraoperative
        tool for enhancement of visual contrast and is able to provide real-time guidance in tumor
        visualization and demarcation. Particularly the use of tumor-specific markers coupled to
        fluorescent imaging moieties show great promise to improve intraoperative staging and allow
        more radical cytoreductive surgery if considered resectable.
  
        The compound that will be studied in this trial is SGM-101, a CEA-specific chimeric antibody
        conjugated with a NIR emitting moiety developed by SurgiMab (Montpellier, France). Anti-CEA
        monoclonal antibodies have been used in more than 100 clinical studies without any toxicity
        concerns. In addition, it has been shown that it is possible to link an anti-CEA monoclonal
        antibody to a near-infrared (NIR) emitting fluorophore. Carcinoembryonic antigen (CEA) is a
        tumor-specific marker that is highly expressed in a number of tumors of epithelial origin
        (such as colorectal carcinoma and pancreas carcinoma) while it is minimally expressed in
        normal adult tissues. CEA, among others like Carbohydrate Antigen 19-9 (CA 19-9) is used as
        diagnostic and prognostic marker during different stages of malignant pancreatic disease.
        From a previous study conducted in the LUMC with this compound in patients with (borderline)
        resectable pancreatic cancer the investigators learned that near-infrared fluorescence
        imaging of pancreatic tumors using a single dose up to 10mg of the anti-CEA targeted
        fluorophore SGM-101 is safe, well-tolerated, feasible and effective. It results in specific
        accumulation of SGM-101 in CEA-expressing primary tumors, peritoneal and liver metastases,
        allowing real-time identification and guidance using intraoperative fluorescence imaging.
        Furthermore, CEA expression on the targeted PDAC tissue is expected to be none to minimally
        influenced by the neoadjuvant treatment, either FOLFIRINOX or a combination of Gemcitabine
        with or without radiotherapy, as described by previous studies. In addition to experience in
        pancreatic tumors, there is ample experience from finalized phase-II and ongoing phase-III
        studies in patient with colorectal carcinoma. A recent study in colorectal cancer patients
        showed that additional malignant lesions were detected and resected using NIR fluorescence
        imaging in 6 out of 17 patients (35%). Moreover, an expansion on this study showed no SGM-101
        related adverse events up to 15 milligrams in 75 patients. There were no trends or clinically
        relevant changes in vital signs, ECGs or laboratory parameters reported. Any changes in the
        laboratory results reported in the follow-up moments were related to the surgical procedure.
        Best imaging results (according to the tumor to background ratio) were achieved with 10
        milligrams injected 3 to 5 days prior to surgery.
  
        This study evaluates the yield of NIR-Fluorescence imaging as additional surgical-tool for
        visualization and assessment of local extent and resectability status of neoadjuvant treated
        localized pancreatic tumors, local lymph node-involvement as well as potential distant
        metastatic disease using a single intravenous dose of 10mg SGM-101.
  
        Main objective: Determination of the performance of SGM-101 as a fluorescent tracer for
        NIR-Fluorescence-guidance (FLI) during surgical pancreatic resections after neoadjuvant
        therapy for assessment of (local) tumor extent and delineation of the primary tumor, local
        lymph nodes and potential distant metastatic disease
  
        Design:
  
        Part A: This is a single-center prospective clinical cohort study in patients with
        neoadjuvant treated non-primarily resectable ((borderline) resectable and locally advanced)
        pancreatic cancer undergoing scheduled surgical resection. A total of 20 patients will be
        prospectively enrolled in this study evaluating the performance of NIR-Fluorescence imaging
        as an additional surgical-tool for the visualization and determination of the local extent of
        primary tumor, lymph node-involvement and occult hepatic and peritoneal metastatic disease in
        patients using a single dose of 10mg of SGM-101. The selected dose is based on the
        pre-clinical and phase I/II results in patients with pancreatic and colorectal cancer.
  
        Part B: Part B is synchronous to part A, to compare and match the TdEV containing blood
        samples from patients participating in part A this trial needs 20 healthy donor control blood
        samples of 30mL to address our exploratory endpoints regarding TdEV's. Therefore in this
        trial 20 healthy volunteers will be asked to participate as anonymous healthy blood donor of
        30mL (3 EDTA tubes) peripheral venous blood for a single visit to donate healthy donor blood.
        The control samples will be used anonymous and there is no further follow-up or additional
        study related activities.
  
        Investigational drug: The Investigational Medicinal Product (IMP) used in part A is the
        injectable conjugate SGM-101 is composed of a chimeric monoclonal antibody specific of CEA,
        bound to a fluorochrome. SGM-101 is manufactured in compliance with Good Manufacturing
        Practice (GMP). It is a sterile solution for injection supplied in 4 mL amber glass vial (5
        mg/mL; 2,3 mL/vial). A dose of 10 mg SGM-101 will be administered intravenously over 30
        minutes 3 to 5 (±4) days prior to surgery.
  
        Imaging system: The Investigational Medical Device (IMD) used in part A is the imaging system
        that will be used in the study is a dedicated NIRF-camera system from Quest Medical Imaging
        (Quest Medical Imaging, Olympus Europe) the Quest Spectrum 2/3.0 Platform, that is optimized
        for measurements in the 700-800nm NIR-spectrum. For this device ample handling-experience for
        end-users exists at the LUMC, gained from standard-of-care and research activities with
        intra-operative NIRF-imaging.
  allocation: N/A
  intervention model: Single Group Assignment
  primary purpose: Treatment
  masking: None (Open Label)
  measure: Intra-operative visualization of neoadjuvant treated pancreatic tumors using Near-infrared fluorescence imaging,
  time frame: Surgery -
  description: The ability to visualize the primary pancreatic tumor, the local tumor extent and resectability status, with adjacent lymph nodes. As well as potential distant metastatic lesions, using SGM-101 and dedicated NIR-imaging systems. Visualization is measured using the tumor-to-background ratio (TBR) in ex-vivo settings. A tumor-to-background ratio (TBR) of at least ≥1.5 provides sufficient contrast for adequate visualization/delineation and will therefore be used as cut-off value.
  measure: Concordance between fluorescent signal and tumor status of resected tissue
  time frame: Through study completion, an average of 3 months
  description: Concordance to pathology results with respect to the presence of cancer and the imaging assessment, based on fluorescent signal and the tumor status (incl. degree of CEA-expression) of biopsied or resected tissue, expressed as accuracy (%), sensitivity (%) and specificity (%)
  measure: Concordance between fluorescent signal and tumor status of resection margins.
  time frame: Through study completion, an average of 3 months
  description: Concordance to pathology results with respect to the presence of cancer and the imaging assessment, based on fluorescent signal and the tumor status (incl. degree of CEA-expression) of biopsied or resected tissue, expressed as accuracy (%), sensitivity (%) and specificity (%)
  arm group label: 10mg, administered 3-5 days before surgery
  arm group type: Experimental
  description: Drug: SGM-101 Intravenous single injection of the targeted NIR fluorophore SGM-101. This targeted 700nm fluorophore developed by SurgiMab S.A.S., Montpellier, France.
  Device: Intraoperative near-infrared fluorescence imaging Intraoperative imaging will be performed with the following CE-marked near-infrared (NIR) fluorescence imaging system: Quest Spectrum imaging platform (v2/3.0). With a NIR-imaging system a potential fluorescent signal of the tumor can be evaluated. Furthermore, the Quest Spectrum platform will also be used for evaluation of ex-vivo fluorescence of resected tissue on the back table (Back table imaging) and pathology department (ex-vivo imaging), which shall be performed during and after every procedure.
  intervention type: Procedure
  intervention name: Fluorescence-guided surgery using CEA-targeted fluorophore SGM-101
  description: Fluorescence-guided surgery using CEA-targeted fluorophore SGM-101
  arm group label: 10mg, administered 3-5 days before surgery
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: N/A
  healthy volunteers: Accepts Healthy Volunteers
  facility: 
  country: Netherlands
  responsible party type: Principal Investigator
  investigator affiliation: Leiden University Medical Center
  investigator full name: Alexander Vahrmeijer
  investigator title: Surgical oncologist, Head of Vahrmeijer Research Lab
  mesh term: Adenocarcinoma
  sharing ipd: No